2 minute read
Campania Bioscience
Name ›
Address/P.O. Box › Postal Code/City › Country › Contact Person › Telephone › Email › Website ›
Social Media › Number of Employees › Founded (year) ›
Areas of Activity ›
Catalent Cell & Gene Therapy
37, Rue Auguste Piccard 6041, Gosselies Belgium Hristina Kostic 00800-8855-6178 solutions@catalent.com biologics.catalent.com/ cell-gene-therapy
IL F
18,000+ 2007
Cell Therapy, iPSC, Viral Vectors, Plasmid DNA, mRNA, Vaccines
Catalent Cell & Gene Therapy is an industry-leading technology, development, and manufacturing partner for advanced therapeutics. Its comprehensive cell therapy portfolio includes a wide range of expertise across a variety of cell types, including CAR-T, TCR, TILs, NKs, iPSCs, and MSCs. With deep expertise in viral vector development, scale-up, and manufacturing for gene therapies and viral vaccines, Catalent is a fullservice partner for plasmid DNA, adeno-associated viral (AAV), lentiviral, and other viral vectors, and oncolytic viruses. An experienced and innovative partner, it has a global network of dedicated, small- and large-scale clinical and commercial manufacturing facilities, including an EMA- and FDA-licensed viral vector facility, and fill/finish capabilities located in the US and Europe. With integrated solutions for plasmid DNA, viral vectors, and autologous and allogeneic cell therapies through to clinical trial packaging and logistics, Catalent can provide full supply chain control, helping innovators get their advanced therapies to patients, faster.
Plasmid DNA Capabilities
Plasmid DNA is a critical raw material for advanced therapeutics, including mRNA and viral vector-based cell and gene therapies and vaccines. Catalent offers plasmid DNA solutions, from supporting early activities such as lead identification to facilitating the transition to GMP manufacturing for clinical and commercial supply.
Our plasmid DNA services include: › CGMP cell banking › R&D and CGMP grade manufacturing › mg to 10+ g scale › Linearised plasmid for mRNA production
With global development and manufacturing facilities, our experienced team is ready to help define and deliver an integrated programme from plasmid DNA to fill and finish for your advanced therapies.
iPSC Services
Our end-to-end value chain offering tackles critical unmet needs in industrialising iPSC workflow. Catalent’s iPSC GMP cell banks utilise specialised reprogramming technology to transform commercial-use donor consented, clinically approved, cord blood collections into HLA-homozygous lines that are immune-compatible with a wide population.
Our dedicated iPSC expert team is comprised of the right blend of iPSC scientists and manufacturing experts working together to develop the next-generation scalable platforms to manufacture iPSC-based therapies.
Our complete toolkit offers the building blocks to industrialise iPSC-based cell therapies: › GMP lines and non-GMP equivalents, including human leukocyte antigen (HLA)-matched cell banks › iPSC reprogramming and differentiation services › Characterisation, manipulation, and release testing of iPSC banks › Cryopreservation and bank storage › Process development, manufacturing, and analytical method development for iPSC therapies
